Abstract
BackgroundType I Interferon (IFN) pathway is activated in Systemic Sclerosis (SSc) and represents a therapeutic target currently being tested in clinical trials, while higher IFNα levels have been also associated...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
